A set of illnesses known as cancer involve abnormal cell proliferation and have the ability to invade or spread to different bodily regions. These stand in contrast to benign tumours, which remain stationary. A lump, unusual bleeding, a persistent cough, unexplained weight loss, and a change in bowel habits are all potential warning signs and symptoms. Chimeric antigen receptors (CARs), often referred to as chimeric immunoreceptors or artificial T cell receptors, are receptor proteins that have been modified so that T cells now have the ability to target a particular antigen. Because they integrate antigen-binding and T cell activation functions into a single receptor, the receptors are chimeric. CAR T cell treatment is a form of treatment in which the patient's immune cells, called T cells, are altered in a lab so that they will adhere to and kill cancer cells. An apheresis machine receives blood from a vein in the patient's arm through a tube, filters out all white blood cells—including T cells—and returns the remaining blood back to the patient. The T cells are then genetically modified in the lab to contain the gene for a unique receptor known as a chimeric antigen receptor (CAR). The CAR T cells are multiplied in a lab before being infused into the patient in large numbers. In order to destroy cancer cells, the CAR T cells can connect to an antigen on the cancer cells.
Cite this article:
Shubhangi Bajirao Suryawanshi, Rahul D Khaire. Review on Car-T Cell Therapy for Cancer Treatment. International Journal of Technology. 2023; 13(1):68-2. doi: 10.52711/2231-3915.2023.00008
Shubhangi Bajirao Suryawanshi, Rahul D Khaire. Review on Car-T Cell Therapy for Cancer Treatment. International Journal of Technology. 2023; 13(1):68-2. doi: 10.52711/2231-3915.2023.00008 Available on: https://ijtonline.com/AbstractView.aspx?PID=2023-13-1-8
1. June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. and Milone, M. C. C. A. R. T cell immunotherapy for human cancer. Science. 359, 1361–1365 (2018).
2. Sadelain, M., Brentjens, R. and Rivière, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388–398 (2013).
3. Sterner, R. M. et al. A graduate-level interdisciplinary curriculum in CAR-T cell therapy. Mayo. Clin. Proc. Innov. Qual. Outcomes. 4, 203–210 (2020)
4. Zhang, G. et al. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci. Rep. 4, 1–8 (2014).
5. Hudecek, M. et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3, 125–135 (2015).
6. Jensen, M. C. and Riddell, S. R. Designing chimeric antigen receptors to effectively and safely target tumors. Curr. Opin. Immunol. 33, 9–15 (2015).
7. Bridgeman, J. S. et al. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J. Immunol. 184, 6938–6949 (2010).
8. Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3, 1 (2018).
9. Gross, G., Waks, T. and Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA. 86, 10024–10028 (1989).
10. Maher, J., Brentjens, R. J., Gunset, G., Rivière, I. and Sadelain, M. Human Tlymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor. Nat. Biotechnol. 20, 70–75 (2002).
11. Abate-Daga, D. et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.
12. Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang WC, Yazaki P, Colcher D, Shively J, Cristea M, Forman SJ, Priceman SJ. Effective targeting of TAG72(+) peritoneal ovarian tumors via regional delivery of CARengineered T cells. Front Immunol. 2018; 9:226
13. Zuo BL, Yan B, Zheng GX, Xi WJ, Zhang X, Yang AG, Jia LT. Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor.
14. Hillerdal V, Essand M. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
15. Bagley SJ, O’Rourke DM. Clinical investigation of CAR T cells for solid tumors: lessons learned and future directions.
16. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
17. Yeku O, Li X, Brentjens RJ. Adoptive T-cell therapy for solid tumors
18. Jung M, Yang Y, McCloskey JE, Zaman M, Vedvyas Y, Zhang X, Stefanova D, Gray KD, Min IM, Zarnegar R. Chimeric antigen receptor T cell therapy targeting ICAM-1 in gastric cancer.
19. Majzner, R. G. and Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219–1226 (2018). 43. Maude, S. L., Teachey, D. T., Porter, D. L. and Grupp, S. A. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.
20. Maude, S. L., Teachey, D. T., Porter, D. L. and Grupp, S. A. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.
21. Rafiq, S., Hackett, C. S. and Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy.
22. Koneru, M., O’Cearbhaill, R., Pendharkar, S., Spriggs, D. R. and Brentjens, R. J. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16 (ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
23. Chekmasova, A. A. et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.
24. Quail, D. F. and Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis.
25. Yin, Y. et al. Checkpoint blockade reverses energy in IL-13Rα2 Humanized scFv-Based CAR T cells to treat murine and canine gliomas.
26. June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. and Milone, M. C. C. A. R. T cell immunotherapy for human cancer.
27. Peter P. Lee (eds.) Tumor Microenvironment
28. Whilding, LM. et al. CAR T-cells targeting the integrin αvβ6 and co-expressing the chemokine receptor cxcr2 demonstrate enhanced homing and efficacy against several solid malignancies
29. Galluzzi L and Martin P: CARs on a highway with roadblocks.
30. Perales MA, Kebriaei P, Kean LS and Sadelain M: Building a safer and faster CAR: Seatbelts, airbags, and CRISPR.
31. Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH and Zhao Y: A versatile system for rapid multiplex genome edited CAR T cell generation.
32. Grupp SA, Laetsch TW, Buechner J, Bittencourt H, Maude SL, Verneris MR, Myers GD, Boyer MW, Rives S, De Moerloose B, et al: Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia
33. Zhao Z, Chen Y, Francisco NM, Zhang Y and Wu M: The application of CAR T cell therapy in hematological malignancies: Advantages and challenges
34. Chmielewski M, Kopecky C, Hombach AA, et al. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.
35. Craddock JA, Lu A, Bear A, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.
36. Juillerat A, Marechal A, Filhol JM, et al. An oxygen sensitive selfdecision making engineered CAR T-cell.
37. Mangestuti Agil, Hening Laswati, Hadi Kuncoro, Burhan Ma’arif. Effect of Ethyl Acetate Fraction of Marsilea crenata Presl. Leaf Extract on Major Histocompatibility Complex Class II Expression in Microglial HMC3 Cell Lines. Research Journal of Pharmacy and Technology. 2021; 14(12):6374-8.
38. Yogita R Mandlik. Immunotherapy, A type of Cancer Treatment. Res. J. Pharma. Dosage Forms and Tech.2020; 12(4):282-284
39. Ganesh G. Dhakad, Sangita P. Shirsat, Kaveri P. Tambe. Review on Immuno-Oncology Agents for Cancer Therapy.Research Journal of Pharmacology and Pharmacodynamics.2022;14(1):47-2.
40. Dibyajyoti Saha, Tarashankar Maity, Mayukh Jana, Supradip Mandal. Cancer Treatment Strategy-An Overview. Asian J. Pharm. Tech. 1(2): April-June 2011; Page 28-33.
41. Simrat Kaur, Prempati Mayanglambam, Deepika Bajwan, Nancy Thakur. Chemotherapy and its Adverse Effects – A Systematic Review. International Journal of Nursing Education and Research. 2022; 10(4):399-2.
42. Arjun Patidar, S.C.Shivhare, Umesh Ateneriya, Sonu Choudhary. A Comprehensive Review on Breast Cancer. Asian J. Nur. Edu. and Research 2(1): Jan.-March 2012; Page 28-32.
43. V. N. Dange, S. J. Shid, C.S. Magdum, S.K. Mohite. A Review on Breast cancer: An Overview. Asian J. Pharm. Res. 2017; 7(1): 49-51.
44. A Case Study on Ovarian Cancer – Palliative Perspective. Asian J. Nur. Edu. and Research 5(3): July- Sept.2015; Page 446-448.
45. Moses. K, P. Karthika, Najarana Patel. Awareness regarding Cervical Cancer among Married Women. Asian J. Nursing Education and Research. 2018; 8(4):515-518.
46. Akshay R. Yadav, Shrinivas K. Mohite. Cancer- A Silent Killer: An Overview. Asian J. Pharm. Res. 2020; 10(3):213-216